Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer

Journal of Clinical Oncology

Volumn 19, Issue 12, 2001, Pages 2983-2993

  Baekelandt, M ^a   Lehne, G ^a   Trope C G ^a   Szanto I ^a   Pfeiffer, P ^a   Gustavssson, B ^a   Kristensen, G B ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; GLYCOPROTEIN P; VALSPODAR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0035875858     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.12.2983     Document Type: Article

References (46)

1. Cancer statistics
2. Epithelial ovarian cancer
3. Biochemistry of multidrug resistance mediated by the multidrug transporter
4. Chemotherapy of advanced ovarian cancer
5. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies
6. P-glycoprotein is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer
7. Clinical correlates of MDRI (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas
8. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance
9. Multidrug resistance: Clinical relevance in solid tumors strategies for circumvention
10. Clinical reversal of drug resistance
11. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
12. Pharmacologic approaches to reversing multidrug resistance
13. Expression of P-glycoprotein on normal lymphocytes: Enhancement of the doxorubicin sensitivity of concanavalin A-responding mouse spleen cells by P-glycoprotein blockers
14. Analysis of the interactions of SDZ PSC 833 ([3'-keto-Bmt1]-Va12]-cyclosporine), a multidrug resistance modulator, with P-glycoprotein
15. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein
16. Cyclosporins as drug resistance modifiers
17. PSC 833, a frontier in modulation of P-glycoprotein mediated multidrug resistance
18. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative
19. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer
20. SDZ PSC 833/paclitaxel in paclitaxel refractory ovarian carcinoma: A phase II trial with renewed responses
21. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel
22. Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin
23. Impact of doxorubicin on survival in advanced ovarian cancer
24. Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells
25. Phase I trial of carboplatin and infusional cyclosporine in advanced malignancy
26. Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: A phase II study of the Gynecologic Oncology Group
27. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors
28. A phase I trial of doxorubicin, paclitaxel and PSC 833 as a modulator of multidrug resistance (MDR) in refractory solid tumors
29. Pharmacological considerations in the modulation of multidrug resistance
30. Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC 833 on colchicine and doxorubicin biliary secretion by the rat in vivo
31. Disruption of the mouse mdrla P-glycoprotein gene leads to deficiency in the blood-brain barrier and to increased sensitivity to drugs
32. Clinical reversal of the multidrug resistance phenotype: True tumour modulation or pharmacokinetic interaction
33. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance
34. P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia
35. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene
36. Phase I study of paclitaxel in combination with a multidrug resistance modulator: PSC 833 (valspodar) in refractory malignancies
37. Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites
38. Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion
39. Drug resistance: Still on the learning curve
40. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833
41. Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance
42. Cyclosporin A and PSC 833 prevent up-regulation of MDR1 expression by anthracyclines in a human multidrug-resistant cell line
43. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin
44. Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents
45. SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells
46. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells